Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mertens, W. C.
Right arrow Articles by Wong, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mertens, W. C.
Right arrow Articles by Wong, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:331-332, 1993
© 1993 European Society for Medical Oncology

brief-report

Gemcitabine in advanced renal cell carcinoma

A phase II study of the National Cancer Institute of Canada Clinical Trials Group

W. C. Mertens1,, E. A. Eisenhauer2, M. Moore3, P. Venner4, D. Stewart5, A. Muldal2 and D. Wong6

1London Regional Cancer Centre London
2National Cancer Institute of Canada, Clinical Trials Group, Queen's University Kingston
3Princess Margaret Hospital Toronto
4Cross Cancer Institute Edmonton
5Ottawa Regional Cancer Centre Ottawa
6Eli Lilly Canada Inc. Toronto, Canada

Correspondence to: Dr. W. C. Mertens, London Regional, Cancer Centre, 790 Commissioners Rd. E. London, Ontario N6A 4L6, Canada

BACKGROUND:: Gemcitabine (2', 2'-difluorodeoxycytidine; dFdC) an anticancer agent with activity in preclinical models, was felt to be a promising new chemotherapy drug which warranted testing in patients with advanced renal cell carcinoma

METHODS:: Eighteen patients with histologically proven metastatic or locally recurrent renal cell carcinoma and bidimensionally measurable disease were accrued to a phase II study of gemcitabine administered intravenously on days 1, 8 and 15 of a 28 day treatment cycle. Initial doses of gemcitabine were 800 mg/m2; doses in subsequent cycles were escalated to a maximum of 1250 mg/m2, toxicity permitting.

RESULTS:: One partial response was seen for a response rate of 6%. Hematologic toxicity was not severe with this dosing schedule; however, two patients developed dyspnea with bronchospasm after repeated injections of drug.

CONCLUSIONS:: The dose and schedule of gemcitabine employed results in only a modest response rate in patients with advanced renal carcinoma. Investigators should be aware of the possibility of dyspnea and bronchospasm developing shortly after gemcitabine administration.

bronchospasm, clinical trial, dyspnea, gemcitabine, renal cell carcinoma, toxicity, 2',2'-difluorodeoxycytidine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C.A. Townsley, K. Chi, D.S. Ernst, K. Belanger, I. Tannock, G.A. Bjarnason, D. Stewart, R. Goel, J.D. Ruether, L.L. Siu, et al.
Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
J. Clin. Oncol., April 15, 2003; 21(8): 1524 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J. Dunton
Management of Treatment-Related Toxicity in Advanced Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 11 - 19.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J.A. van Moorsel, G. J. Peters, and H. M. Pinedo
Gemcitabine: Future Prospects of Single-Agent and Combination Studies
Oncologist, June 1, 1997; 2(3): 127 - 134.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.